BERNAMA - LOTUS, ALVOGEN, NRX PHARMACEUTICALS COLLABORATE TO DEVELOP AND COMMERCIALISE NRX-101
LOTUS, ALVOGEN, NRX PHARMACEUTICALS COLLABORATE TO DEVELOP AND COMMERCIALISE NRX-101
Stay updated with breaking news from Alvogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LOTUS, ALVOGEN, NRX PHARMACEUTICALS COLLABORATE TO DEVELOP AND COMMERCIALISE NRX-101
NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expirySTOUGHTON, Mass., Dec. 22, 2022 -- Collegium Pharmaceutical, Inc. , a leading, diversified specialty pharmaceutical... | December 22, 2022
The Consortium jointly, through Aztiq II HoldCo, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo
Natco Pharma jumped 6.2% to Rs 884.35 after the company received final approval for everolimus tablets in the US market.Natco Pharma announced that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its abbreviated new drug application (ANDA) for everolimus tablets (a generic version of Afinitor) from the US Food and Drug Administration (USFDA). BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and licen...